Honest reviews of 89+ online health providers across GLP-1 weight loss, TRT, ED, hair loss, women's health, longevity, peptides, and primary care. Compare pricing, clinical oversight, and real patient experiences.
From week 36 to week 88, continued tirzepatide produced 5.5% further average weight loss; switching to placebo was associated with 14.0% average regain.
670 adults with obesity or overweight plus a weight-related complication, excluding diabetes, who completed a 36-week tirzepatide lead-in; 88 weeks total; 52-week randomized period. Read the linked peer-reviewed source for the full methodology, findings, and limitations.
Aronne et al., JAMA 2024 · SURMOUNT-4